[Articles] Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial

The venetoclax plus azacitidine regimen showed a manageable safety profile and promising activity as salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Given the limited sample size and single-arm design nature, further confirmatory trials are warranted to validate its efficacy as a potential salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia.